Recent advances in rheumatoid arthritis (RA) research are changing how this complex condition is prevented and treated, as highlighted at EULAR 2025 by Dr. Diane van der Woude. In her review of thousands of new RA studies, she underscored promising data around supplements and disease-modifying therapies, offering new hope for at-risk individuals and those already managing the disease.
Supplements and Prevention
Studies show that vitamin D and fish oil, particularly omega-3 polyunsaturated fatty acids, have drawn interest for their inflammation-regulating and immune-modulating effects. Large-scale human trials like the VITAL study found that supplementing with 2,000 IU/day of vitamin D or 1,000 mg/day of omega-3 fatty acids led to a notable reduction in autoimmune disease rates over 5 years: 22% for vitamin D and 15% for omega-3s. However, these benefits from vitamin D did not last after supplementation stopped, while omega-3 fatty acids continued to show a persistent protective effect. This suggests that long-term benefits may depend on ongoing use and that fatty acids, in particular, could play a sustained role in RA risk reduction.
Preventive Therapies and New Trials
Beyond supplements, researchers are focusing on existing disease-modifying anti-rheumatic drugs (DMARDs) and biologics for prevention. One important study, APIPPRA, evaluated abatacept (a biologic therapy): more than 200 patients with high risk for RA received either the drug or a placebo for one year, and researchers tracked new RA cases over a second year. Results were optimistic—only 25% of those treated with abatacept developed RA compared to 37% in the placebo group, suggesting the medication’s potential for delaying or preventing disease in high-risk patients. These findings highlight a growing emphasis on proactive treatment in those with early symptoms or positive biomarkers, aiming to intervene before full-blown RA develops.
Looking Ahead
Ongoing research continues to clarify how and when these interventions are most effective. The next wave of studies is needed to determine the durability of benefits, optimal timing, and possible side effects. If these preventive strategies prove successful, they could transform not only how RA is managed but also how autoimmune disease risk is approached for the broader population.
